DOCSLIB.ORG

Patient Services, Inc. 2014 Annual Report Table of Contents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Patient Services, Inc. 2014 Annual Report Table of Contents Patient Services, Inc. 2014 Annual Report Table of ConTenTs 2014 Board of Directors and Sponsors .......................................................................................... 3 Pharmaceutical, Provider Industries, Corporate, Government and Individual Sponsors ............ 3-5 Ways to Support PSI ..................................................................................................................... 6 2014 Executive Message ................................................................................................................ 7 Marketing and Development ........................................................................................................ 8 Government Relations .................................................................................................................. 9 Operations and Program Reimbursement ....................................................................................10 PSI Traditional Programs ....................................................................................................... 11-13 IT Department ............................................................................................................................14 ACCESS® Program ......................................................................................................................15 Message from our Board Treasurer ..............................................................................................16 Statement of Activities .................................................................................................................17 Financial Statistics .......................................................................................................................18 PSI State Initiatives ......................................................................................................................19 Patient Testimonials ................................................................................................................20-21 About PSI ................................................................................................................................... 22 - 2 - 2014 board of directors and sponsors VoTing MeMbers non-VoTing MeMber Dana A. Kuhn, PhD President/Co-Founder Art Wood Gary W. Cross Board Chair Senior Vice President, Marketing/Development Danielle Nance, MD Vice Chair Russell E. Phillips Jr., CPA, CVA Board Treasurer Brian L. Fink, JD Board Secretary Steven Ayers, MBA Board Member Terrie L. Glass, LCSW Board Member Mark Edward Mula, RPh Board Member Mitch Mula Board Member pharMaCeuTiCal, proVider indusTries, CorporaTe, goVernMenT and indiVidual sponsors 16-25 Years of Donations to PSI 6-10 Years of Donations to PSI Baxter International Inc. Alpha Net, Inc. CVSCaremark ARJ Infusion Services Factor Support Network BioRx Boston Hemophilia Treatment Center, 11-15 Years of Donations to PSI Brigham & Women’s Physician Organization, Inc. American Service and Product Center for Bleeding and Clotting Disorders (formerly Fairview) Bayer Healthcare Coram Hemophilia Services CSL Behring LLC Good Search Eastern Pennsylvania, NHF Hemophilia of North Carolina (formerly Delaware Valley Chapter NHF) MedPro RX, Inc. Florida Hemophilia Association Nationwide Children’s Hospital Genzyme Pfizer, Inc. Grifols Redchip of Nevada Hemophilia Association of the Capital Area Specialty Therapeutic Care National Cornerstone Healthcare Services, Inc. The Hemophilia Center of Western PA Novartis Pharmaceuticals Corporation United Way Novo Nordisk Inc. ViroPharma Incorporated University of PA Medical Center - 3 - pharMaCeuTiCal, proVider indusTries, CorporaTe, goVernMenT, and indiVidual sponsors 1-5 Years of Donations to PSI Aegerion Pharmaceuticals Indiana Hemophilia & Thrombosis Affinity Biotech Insys Therapeutics Alexion Pharmaceuticals, Inc. New Venture Fund Ariad Pharmaceuticals Positudes Inc. Avanir Pharmaceuticals, Inc. Retrophin Biogen Idec Salix Pharmaceuticals Boehringer Ingelheim Pharmaceuticals Shire Human Genetic Therapies, Inc. CareFusion Corporation Sigma-Tau Pharmaceuticals Diplomat Specialty Pharmacy The Hemophilia Alliance Dohmen Life Science Services The Tissue Foundation (anonymous) Dyax Corporation United Therapeutics Corporation Ethical Factor, RX Vanda Hemophilia of Georgia Vanguard Charitable Endowment Program Hemophilia Outreach Center ViroPharma Incorporated PSI 25Th anniVersary gala sponsors Alexion Pharmaceuticals, Inc Grifols Amicus Theraputics Hemophilia Foundation of Maryland ASD Specialty Healthcare Immune Deficiency Foundation Baxter Healthcare Insys Therapeutics Bayer Healthcare Pharmaceuticals National Cornerstone Healthcare Services, Inc. Biogen Idec Next IT Corporation Biomarin Pharmaceuticals Novartis Pharmaceuticals Corporation Boehringer Ingelheim Pharmaceuticals Onco360 BriovaRx PharmaStrategies, Inc Carefusion Corporation Sigma-Tau Pharmaceuticals CSI Specialty Group Thorn Run Partners LLC CSL Behring LLC Virginia Hemophilia Foundation Ethical Factor, Rx goVernMenT sponsors (Years that Grants Have Been Awarded to PSI) Commonwealth of Kentucky Commonwealth of Virginia South Carolina Department of Health 15 Years 18 Years 6 Years - 4 - pharMaCeuTiCal, proVider indusTries, CorporaTe, goVernMenT, and indiVidual sponsors indiVidual sponsors Adele P. Mohrfeld Dorothy A. Creed Joan C. Gill Meredith Friedman Alec & Nan Parker Douglas & Carolyn Byrd Joe Boyd Michael & Carol Ross-Spang Allen Wolaver Douglas Appelgren John & Vivian Trainor Michael Dannemiller Andrew Matthews Dwight & Brenda Baxter John & Christine Lipski Michael McKay Ann & Shawn J. Smolsky Eileen Bostwick John Reed Michele Plaut Ann Davis Elaine J. Spang Joseph & Margaret Biegalski Mr. & Mrs. Jonathan Yoser Anthony & Jill Bentivegna Eliza P. Lipton Joseph M. & Katherine Nonna MacKenzie Beatriz G. Carbajal Ellen J. Zmolek Schaefer Omar Abhai Bobby L. Evans Ellis & Linda Sulser Joshua Thoms Patricia T. Keever Bonnie Greenwald Elric Parker Joyce M. Jackson Penelope M. Taylor Boris & Julia Kogut Eric & Karen Langberg Joyner Bible Class Peter J. Ledwedge Brett Kaplicer Erin M. Font Karen J. Chamblin Estate Philip & Theresa Edelstein Brian & Lisa Lees Ethel F. Lane Karen Savia Phyllis Kennedy Brian Johnson Evan Ezell Katherine & Robert Segi Raymond & Dorothy Spang Bryan & Jennifer Meyers Florence Lafauce Kelly & William Eagen Raymond & Margaret Watson Bryan & Lynn Drost Florence Weyer Kenneth & Dana Newman Regina Savage Carl A. Weixler Frank & Patricia Berg Krishna & Chitra Maridi Robert & Evelyn Dise Carlo Acanfora Frank J. Coluccio Kulla W. Ficare Robert & Heidi Schnapp Caroline Habbert Gaye & Lawrence Pecker Larry Cairns Robert & Holli Ehrlich Carolyn A. Hume George & Carol Fagan Laura S. Winner Russell & Carol Doke Catherine M. Schetter Georgia Davis Lauren Franck Samantha Raymon Charles & Ruth Ridge Gina Solomon Linda Gannon Shirley L. Lewus Charlotte Worstall Hans Schiessl Lori & Cary Munk Shu-Lun Weinheimer Curtis & Shirley Shipp Harold & Janice Cumbie Lori Brownlee Steven & Elisa Grossbard Dale Quandt Harold Duckworth Lou Krappes Susan Clouse Dan & Eve Sperling Isabel Dellilo Margaret & William Rilling Susan Hughes Dannyl & Victoria Moreland Jacklyn M. Rollo Margaret Bauer Suzanne M. Klar Data Listing Services, LLC James G. Cooper Margaret L. Poole Thomas & Ann Marie David & Susan Posner James May Marion Toby Koch Hightower David Barash Janet M. & Jerry C. Petersen Marshall & Beverly Weinstein Thomas & Diana Jenkins David C. Guyton, Jr Jennifer Grossman Mary & Paschal Dealoia Thomas & Edna Taylor Debra K. Scott Jill & William Neff Mary Ellen Prince William O. Buchanan Dolores Damron Jill E. Montag Mary Lou G. Bolger Donald Rosser Jill Rogers Mary Margaret D. Voorhies Donna & Douglas Brower Jo Ann Elardo Mary Rugen PSI sTaff MeMbers Lisa Estes Jason Kuhn Emily Ledbetter Neil Millhiser, JD Jennifer Snead-Smith, Executive Assistant Operations Analyst & Mail Support General Manager SPHR Support Services Manager Director of Human Resources - 5 - Ways To supporT PSI For 25 years, PSI has been fortunate to receive financial Ways to Give support from thousands of donors who simply want to help Donate online: PSI welcomes donations of all sizes. Your chronically-ill patients afford the cost of their treatment. In generous gift will help patients pay for expensive premiums or 2014, PSI received its seventh consecutive 4-star Charity co-payments they otherwise wouldn’t be able to afford. To make Navigator rating and was also recognized as a GuideStar silver a secure online donation, please visit www.patientservicesinc.org. preferred member for being a leading symbol of transparency and accountability. “We always aim to be a fiscally responsible Donate by mail: To donate by mail, simply mail your organization while increasing the capacity and outreach of our check to Patient Services, Inc. at P.O. Box 5930, Midlothian, Virginia 23112. programs to assist chronically ill patients,” said Dana Kuhn, Ph.D. “Our goal is to restore hope and health to their lives by Make a donation in someone’s name: An Honorary making treatment affordable and accessible. This 4-star rating or Memorial Donation offers a thoughtful way to honor the is a testament to our upstanding business practices.” We hope memory of a loved one or commemorate important occasions that you will find it in your heart today to help us continue while supporting PSI. Your generous donation will directly to provide a financial safety net to the chronically ill. Your support PSI’s
Load more

Recommended publications
  • Uniqure N.V. Paasheuvelweg 25A 1105BP Amsterdam the Netherlands +1-339-970-7000
    uniQure N.V. Paasheuvelweg 25a 1105BP Amsterdam The Netherlands +1-339-970-7000 NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS To be held on September 14, 2017 To the Shareholders of uniQure N.V.: Notice is hereby given that an Extraordinary General Meeting of Shareholders (the “Extraordinary Meeting”) of uniQure N.V., a public company with limited liability ( naamloze vennootschap ) under the laws of the Netherlands (the “Company,” “uniQure,” and “we”), will be held on September 14, 2017, at 9:30 a.m., Central European Summer Time, at the Company’s principal executive offices located at Paasheuvelweg 25a, 1105BP Amsterdam, the Netherlands, for the following purposes: I. Opening and announcements; II. Appointment of Jeremy P. Springhorn, Ph.D. as a non-executive director (voting proposal no. 1); III. Appointment of Madhavan Balachandran as a non-executive director (voting proposal no. 2); IV Any other business that may properly come before the meeting or any adjournment of the meeting; and V. Closing of the meeting. Each person authorized to attend the Extraordinary Meeting may inspect the Agenda at the office of uniQure. Our Board of Directors (our “Board”) recommends that you vote “FOR” each of the voting proposals noted above. The record date is set at the close of business on August 17, 2017 EST and, therefore, only the Company’s shareholders of record at the close of business on August 17, 2017 EST are entitled to receive this notice (this “Notice”) and to vote at the Extraordinary Meeting and any adjournment thereof. Only shareholders who have given notice in writing to the Company by September 12, 2017 of their intention to attend the Extraordinary Meeting in person are entitled to attend the Extraordinary Meeting in person.
    [Show full text]
  • CB2013 Committee and Board Disclosureauditlist 9.10.13
    2013-2014 Conflict of Interest Disclosure AST Activity Participant First Name Participant Last Name Degree DisclosureDate Disclsoure Item Committee Member Reza Abdi MD 4/22/2013 No Relevant Financial Relationships Committee Member Sameh R. Abul-Ezz MD, PhD 4/16/2013 No Relevant Financial Relationships Committee Member Deborah B. Adey MD 4/15/2013 No Relevant Financial Relationships Committee Member Enver Akalin MD 4/16/2013 Consultant relationship with Pfizer Fellows 2013 Maria-Luisa Alegre MD, PhD 7/12/2013 No Relevant Financial Relationships Committee Member Alessandrini Alessandro PhD 4/29/2013 No Relevant Financial Relationships Board Member James S. Allan MD 5/3/2013 Committee Member No Relevant Financial Relationships Rita R. Alloway PharmD, FCCP Grant Support relationship with Astellas Grant Support relationship with BMS Grant Support relationship with Novartis Grant Support relationship with Lifecycle Grant Support relationship with Millenium Grant Support relationship with Pfizer (previously Wyeth) Grant Support relationship with Genentech (previously Roche) Board Member Grant Support relationship with Viropharma Committee Member Grant Support relationship with Alexion Fellows 2013 7/18/2013 Grant Support relationship with Sanofi (previously Genzyme, previously Sangstat) Committee Member Sandra Amaral MD, MHS 6/18/2013 Other relationship with Bristol Myers-Squibb Hatem Amer MD 5/6/2013 Grant Support relationship with Abbott Laborartories. Committee Member Other relationship with Massacheussetts Medical Society. Committee Member William Applegate No Relevant Financial Relationships Committee Member Alexander Aussi BSN, RN, MBA 4/22/2013 Consultant relationship with Total Transplant Advantage, LLC Committee Member Jamil Azzi MD 4/30/2013 No Relevant Financial Relationships Committee Member Fellows 2013 Mark L.
    [Show full text]
  • AMGEN INC. V. SANOFI
    Case: 20-1074 Document: 159 Page: 1 Filed: 06/21/2021 NOTE: This order is nonprecedential. United States Court of Appeals for the Federal Circuit ______________________ AMGEN INC., AMGEN MANUFACTURING, LIMITED, AMGEN USA, INC., Plaintiffs-Appellants v. SANOFI, AVENTISUB LLC, FKA AVENTIS PHARMACEUTICALS INC., REGENERON PHARMACEUTICALS INC., SANOFI-AVENTIS U.S. LLC, Defendants-Appellees ______________________ 2020-1074 ______________________ Appeal from the United States District Court for the District of Delaware in Nos. 1:14-cv-01317-RGA, 1:14-cv- 01349-RGA, 1:14-cv-01393-RGA, 1:14-cv-01414-RGA, Judge Richard G. Andrews. ______________________ JEFFREY A. LAMKEN, MoloLamken LLP, Washington, DC, filed a petition for rehearing en banc for plaintiffs-ap- pellants. Also represented by SARAH JUSTINE NEWMAN, MICHAEL GREGORY PATTILLO, JR.; SARA MARGOLIS, New York, NY; EMILY JOHNSON, ERICA S. OLSON, STEVEN TANG, STUART WATT, WENDY A. WHITEFORD, Amgen Inc., Thou- sand Oaks, CA; KEITH HUMMEL, Cravath Swaine & Moore LLP, New York, NY; WILLIAM G. GAEDE, III, McDermott Case: 20-1074 Document: 159 Page: 2 Filed: 06/21/2021 2 AMGEN INC. v. SANOFI Will & Emery LLP, Menlo Park, CA; CHRISTOPHER B. MEAD, Schertler Onorato Mead & Sears LLP, Washington, DC; JAMES L. HIGGINS, MELANIE K. SHARP, Young, Cona- way, Stargatt & Taylor, LLP, Wilmington, DE. Plaintiff- appellant Amgen Inc. also represented by SARAH CHAPIN COLUMBIA, McDermott, Will & Emery LLP, Boston, MA; LAUREN MARTIN, Quinn Emanuel Urquhart & Sullivan LLP, Boston, MA. MATTHEW WOLF, Arnold & Porter Kaye Scholer LLP, Washington, DC, filed a response for defendants-appellees. Also represented by VICTORIA REINES; DAVID K. BARR, DANIEL REISNER, New York, NY; DEBORAH E.
    [Show full text]
  • 2012 Financial Markets Preview Living Creatively
    REPRINT FROM JANUARY 2, 2012 BioCentury ™ THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint • Page 1 of 8 2012 Financial Markets Preview Living creatively By Stacy Lawrence “As the capital markets Viren Mehta of Mehta Partners. “Many Senior Writer companies don’t have any option but to For small, early stage biotech compa- continue to be difficult, raise at lower valuations.” nies, 2012 could be the year of living traditional investors are able He added: “Many companies are not creatively. able to defer any longer. The moment Although public biotechs raised more to extract terms that are comes for many companies when they funds last year than ever before, the vast have to swallow hard and accept painful majority of the money was debt financing more and more onerous.” dilution.” by established companies with marketed products. Thus while the overall numbers Todd Wyche, Brinson Patrick look good and are likely to continue to do Cash on hand so, precommercial companies will have to large and mid-cap companies (see “The Market volatility and macroeconomic get creative with their financings. 1% Effect,” page 2). risk had most buysiders sitting on the Many of these companies avoided rais- In 2011, public biotechs raised $43 sidelines through the back half of 2011. ing money in 2011 because they didn’t billion, easily eclipsing the record $33.1 Bankers are hopeful that this year will be like the valuations, but Wall Streeters say billion in 2000. But debt accounted for more stable, in which case investors might they are now running out of cash. As a 82% of the total dollars raised, compared be willing to support more deal flow dur- result, they will have to use the tricks at to only 19% in 2000 (see “Debt Domi- ing 1H12 (see “Fear Factor,” page 5).
    [Show full text]
  • Surescripts, Llc As Amicus Curiae in Support of Petitioners in No
    Nos. 19-508 and 19-825 In the Supreme Court of the United States ———————————— AMG CAPITAL MANAGEMENT, LLC, ET AL., Petitioners, v. FEDERAL TRADE COMMISSION, Respondent. ———————————— FEDERAL TRADE COMMISSION, Petitioner, v. CREDIT BUREAU CENTER, LLC, ET AL., Respondents. ———————————— ON WRITS OF CERTIORARI TO THE UNITED STATES COURTS OF APPEALS FOR THE SEVENTH AND NINTH CIRCUITS ———————————— BRIEF OF SURESCRIPTS, LLC AS AMICUS CURIAE IN SUPPORT OF PETITIONERS IN NO. 19-508 AND RESPONDENTS IN NO. 19-825 ———————————— ALFRED C. PFEIFFER, JR. ROMAN MARTINEZ LATHAM & WATKINS LLP Counsel of Record 505 Montgomery Street AMANDA P. REEVES Suite 2000 ALLYSON M. MALTAS San Francisco, CA 94111 DOUGLAS C. TIFFT BLAKE E. STAFFORD JAMES A. TOMBERLIN* LATHAM & WATKINS LLP 555 Eleventh Street, NW Suite 1000 Washington, DC 20004 (202) 637-2200 [email protected] Counsel for Amicus Curiae Surescripts, LLC TABLE OF CONTENTS Page TABLE OF AUTHORITIES ...................................... ii INTEREST OF AMICUS CURIAE ............................1 SUMMARY OF ARGUMENT .....................................3 ARGUMENT ...............................................................5 I. The FTC Has Increasingly Wielded Section 13(b) To Obtain Monetary Relief In Antitrust Cases ................................................5 II. The FTC’s Antitrust Authority Confirms That Section 13(b) Does Not Authorize Monetary Relief ..................................................22 CONCLUSION ..........................................................32 ii TABLE OF AUTHORITIES Page(s) CASES Apple Inc. v. Pepper, 139 S. Ct. 1514 (2019) .......................................... 13 Armstrong v. Exceptional Child Center, Inc., 575 U.S. 320 (2015) .............................................. 23 Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (2007) .............................................. 26 In re Cardinal Health, Inc., No. 101-0006, 2015 WL 1849040 (F.T.C. Apr. 17, 2015) ........................ 19, 20, 28, 30 Credit Suisse Securities (USA) LLC v. Billing, 551 U.S.
    [Show full text]
  • Federal Register/Vol. 84, No. 232/Tuesday, December 3, 2019
    Federal Register / Vol. 84, No. 232 / Tuesday, December 3, 2019 / Notices 66191 the Assistant Attorney General, patterns, devices, manufacturing filed with and accepted, subject to final developed the HSR Rules and the processes, or customer names. approval, by the Commission, has been corresponding Notification and Report placed on the public record for a period Form. Heather Hippsley, of thirty (30) days. The following On September 11, 2019, the Deputy General Counsel. Analysis to Aid Public Comment Commission sought comment on the [FR Doc. 2019–26075 Filed 12–2–19; 8:45 am] describes the terms of the consent reporting requirements associated with BILLING CODE 6750–01–P agreement and the allegations in the the HSR Rules and corresponding complaint. An electronic copy of the Notification and Report Form. 84 FR full text of the consent agreement 47951. No relevant comments were FEDERAL TRADE COMMISSION package can be obtained from the FTC received. Pursuant to the OMB [File No. 191 0061] Home Page (for November 15, 2019), on regulations, 5 CFR part 1320, that the World Wide Web, at https:// implement the PRA, 44 U.S.C. 3501 et Bristol-Myers Squibb Company and www.ftc.gov/news-events/commission- seq., the FTC is providing this second Celgene Corporation; Analysis of actions. opportunity for public comment while Agreement Containing Consent Orders You can file a comment online or on seeking OMB approval to renew the pre- To Aid Public Comment paper. For the Commission to consider existing clearance for those information your comment, we must receive it on or collection requirements.
    [Show full text]
  • Amgen Inc. V. Sanofi, No
    No. IN THE Supreme Court of the United States ———— AMGEN INC., AMGEN MANUFACTURING LIMITED, AND AMGEN USA, INC., Petitioners, v. SANOFI, AVENTISUB LLC, REGENERON PHARMACEUTICALS INC., AND SANOFI-AVENTIS U.S., LLC, Respondents. ———— On Petition for a Writ of Certiorari to the United States Court of Appeals for the Federal Circuit ———— PETITION FOR A WRIT OF CERTIORARI ———— STUART L. WATT JEFFREY A. LAMKEN WENDY A. WHITEFORD Counsel of Record ERICA S. OLSON MICHAEL G. PATTILLO, JR. EMILY C. JOHNSON SARAH J. NEWMAN AMGEN INC. MOLOLAMKEN LLP One Amgen Center Drive The Watergate, Suite 660 Thousand Oaks, CA 91320 600 New Hampshire Ave., NW (805) 447-1000 Washington, D.C. 20037 (202) 556-2000 [email protected] Counsel for Petitioners :,/621(3(635,17,1*&2,1&± ±:$6+,1*721'& QUESTION PRESENTED The 1952 Patent Act requires patents to “contain a written description of the invention, and of the manner and process of making and using it.” 35 U.S.C. §112(a). The “written description” must be “in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same.” Ibid. “The object of the statute is to require the patentee to describe his invention so that others may construct and use it after the expiration of the patent.” Schriber-Schroth Co. v. Cleveland Tr. Co., 305 U.S. 47, 57 (1938). The Federal Circuit has construed §112(a) as impos- ing separate “written description” and “enablement” re- quirements subject to different standards.
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • Shire Acquisition of Viropharma - Strategic Move to Strengthen Shire’S Rare Disease Business - Augments Already Strong Growth Prospects
    Shire acquisition of ViroPharma - Strategic move to strengthen Shire’s Rare Disease business - Augments already strong growth prospects Flemming Ornskov, MD Chief Executive Officer Graham Hetherington Chief Financial Officer Our purpose We enable people with life-altering conditions to lead better lives. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements included in this communication that are not historical facts are forward-looking statements. Forward-looking statements involve a number of risks and uncertainties and are subject to change at any time. In the event such risks or uncertainties materialize, results could be materially adversely affected. The risks and uncertainties include, but are not limited to, that: •Shire’s proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement; •a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not be obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied; •ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma’s business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources; •difficulties in integrating ViroPharma into Shire may lead to the combined company not being able to realize the expected operating efficiencies, cost savings, revenue enhancements, synergies or other benefits at the time anticipated or at all; and risks and uncertainties detailed from time to time in Shire’s or ViroPharma’s filings with the U.S.
    [Show full text]
  • Amgen 2008 Annual Report and Financial Summary Pioneering Science Delivers Vital Medicines
    Amgen 2008 Annual Report and Financial Summary Pioneering science delivers vital medicines About Amgen Products Amgen discovers, develops, manufactures Aranesp® (darbepoetin alfa) and delivers innovative human therapeutics. ® A biotechnology pioneer since 1980, Amgen Enbrel (etanercept) was one of the fi rst companies to realize ® the new science’s promise by bringing EPOGEN (Epoetin alfa) safe and effective medicines from the lab Neulasta® (pegfi lgrastim) to the manufacturing plant to patients. NEUPOGEN® (Filgrastim) Amgen therapeutics have changed the practice of medicine, helping millions of Nplate® (romiplostim) people around the world in the fi ght against ® cancer, kidney disease, rheumatoid Sensipar (cinacalcet) arthritis and other serious illnesses, and so Vectibix® (panitumumab) far, more than 15 million patients worldwide have been treated with Amgen products. With a broad and deep pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives. 0405 06 07 08 0405 06 07 08 0405 06 07 08 0405 06 07 08 Total revenues “Adjusted” earnings Cash fl ow from “Adjusted” research and ($ in millions) per share (EPS)* operations development (R&D) expenses* (Diluted) ($ in millions) ($ in millions) 2008 $15,003 2008 $4.55 2008 $5,988 2008 $2,910 2007 14,771 2007 4.29 2007 5,401 2007 3,064 2006 14,268 2006 3.90 2006 5,389 2006 3,191 2005 12,430 2005 3.20 2005 4,911 2005 2,302 2004 10,550 2004 2.40 2004 3,697 2004 1,996 * “ Adjusted” EPS and “adjusted” R&D expenses are non-GAAP fi nancial measures. See page 8 for reconciliations of these non-GAAP fi nancial measures to U.S.
    [Show full text]
  • UNITED STATES SECURITIES and EXCHANGE COMMISSION Form
    Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☒ 1934 For the fiscal year ended December 31, 2008 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT ☐ OF 1934 Commission file number 000-12477 Amgen Inc. (Exact name of registrant as specified in its charter) Delaware 95-3540776 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) One Amgen Center Drive, 91320-1799 Thousand Oaks, California (Zip Code) (Address of principal executive offices) (805) 447-1000 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(g) of the Act: Common stock, $0.0001 par value; preferred share purchase rights (Title of class) Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.
    [Show full text]
  • Package Insert Has Been Approved by the U.S
    HIGHLIGHTS OF PRESCRIBING INFORMATION **Doses up to 1,000 U every 3 to 4 days may be considered based on These highlights do not include all the information needed to use individual patient response. ® CINRYZE safely and effectively. See full prescribing information for ---------------------- DOSAGE FORMS AND STRENGTHS -------------------- CINRYZE. Approximately 500 Units (lyophilized) in an 8 mL vial. (3) CINRYZE (C1 Esterase Inhibitor [Human]) ---------------------------- CONTRAINDICATIONS ------------------------------- For Intravenous Use, Freeze-Dried Powder for Reconstitution Patients who have manifested life-threatening immediate hypersensitivity Initial U.S. Approval: 2008. reactions, including anaphylaxis, to the product (4). --------------------------- RECENT MAJOR CHANGES -------------------------- ----------------------------- WARNINGS/PRECAUTIONS ------------------------ • Indications and Usage (1) 06/2018 • Hypersensitivity reactions may occur. Have epinephrine immediately • Dosage and Administration (2.1) 06/2018 available for treatment of acute severe hypersensitivity reaction (5.1) • --------------------------- INDICATIONS AND USAGE --------------------------- Serious arterial and venous thromboembolic (TE) events have been CINRYZE is a C1 esterase inhibitor indicated for routine prophylaxis against reported at the recommended dose of C1 Esterase Inhibitor (Human) angioedema attacks in adults, adolescents and pediatric patients (6 years of products, including CINRYZE, following administration in patients with age and older)
    [Show full text]